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Inhibiting mevalonate pathway 
enzymes increases stromal 
cell resilience to a cholesterol-
dependent cytolysin
Sholeem Griffin1, Giulio Preta1,2 & Iain Martin Sheldon1
Animal health depends on the ability of immune cells to kill invading pathogens, and on the resilience 
of tissues to tolerate the presence of pathogens. Trueperella pyogenes causes tissue pathology in 
many mammals by secreting a cholesterol-dependent cytolysin, pyolysin (PLO), which targets stromal 
cells. Cellular cholesterol is derived from squalene, which is synthesized via the mevalonate pathway 
enzymes, including HMGCR, FDPS and FDFT1. The present study tested the hypothesis that inhibiting 
enzymes in the mevalonate pathway to reduce cellular cholesterol increases the resilience of stromal 
cells to PLO. We first verified that depleting cellular cholesterol with methyl-β-cyclodextrin increased 
the resilience of stromal cells to PLO. We then used siRNA to deplete mevalonate pathway enzyme 
gene expression, and used pharmaceutical inhibitors, atorvastatin, alendronate or zaragozic acid to 
inhibit the activity of HMGCR, FDPS and FDFT1, respectively. These approaches successfully reduced 
cellular cholesterol abundance, but mevalonate pathway enzymes did not affect cellular resilience 
equally. Inhibiting FDFT1 was most effective, with zaragozic acid reducing the impact of PLO on cell 
viability. The present study provides evidence that inhibiting FDFT1 increases stromal cell resilience to a 
cholesterol-dependent cytolysin.
Health and the ability to counter pathogenic microbes depends on an organism’s immunity and resilience1,2. 
Immunity, or resistance, is the ability to reduce the pathogen burden by killing infecting microbes. Resilience, 
or tolerance, is the ability to limit the impact of pathogens on health, by tolerating a given microbial burden2–4. 
The ability to tolerate pathogenic bacteria largely depends on the resilience of the host’s tissue cells to damaging 
bacterial virulence factors. Cholesterol-dependent cytolysins are a common virulence factor secreted by patho-
genic bacteria, and they have a high affinity for cholesterol in the plasma membrane of mammalian cells, where 
they form 30–50 nm diameter pores5,6. These pores allow leakage of molecules across the plasma membrane, 
resulting in cell death and tissue damage. Most cellular cholesterol is located in the plasma membrane of animal 
cells, where it constitutes almost half of the lipid molecules7. Cholesterol synthesis depends on the production 
of squalene by the mevalonate pathway8. The mevalonate pathway enzymes are common drug targets, used to 
limit cellular cholesterol synthesis for the control of hypercholesterolemia9. Here we explored whether inhib-
iting the mevalonate pathway to reduce cellular cholesterol in tissue cells could also increase their resilience to 
cholesterol-dependent cytolysins.
Trueperella pyogenes is a Gram-positive bacterium found on the skin and mucosa of many animals, and it 
causes pathology in several tissues, including mucosa, liver, and skin10. Postpartum uterine disease in cattle is 
the most economically important disease associated with T. pyogenes infection, typically affecting 20 to 40% of 
animals after parturition11–13. Uterine disease costs the USA and EU dairy industry about $2 billion/year in lost 
production, infertility, and treatment costs11. The presence of T. pyogenes correlates with the severity of endome-
trial pathology, the extent of the subsequent infertility, and infusion of T. pyogenes recapitulates the disease14–16. 
Trueperella pyogenes causes inflammation and damage of the stromal compartment of the endometrium, once 
the surface epithelium is breached during parturition. The main virulence factor secreted by T. pyogenes is a 
cholesterol-dependent cytolysin, pyolysin (PLO)10. Bovine endometrial stromal cells are highly sensitive to 
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cytolysis caused by PLO16. Whilst antimicrobial therapy limits the severity of disease, there are no treatments to 
increase the ability of tissues to tolerate T. pyogenes. The gap in knowledge is how to manipulate cellular resilience 
to help tissues tolerate pathogens.
There are three pools of cholesterol in the plasma membrane of cells: an essential pool, a sphingomye-
lin sequestered pool, and a labile pool of cholesterol17. The labile cholesterol can be depleted in vitro using 
methyl-β-cyclodextrin (MBCD), which is a cyclic oligosaccharide that binds cholesterol18,19. Reducing cellular 
cholesterol with MBCD increases stromal cell resilience to PLO16,20. Cellular cholesterol abundance is highly reg-
ulated and depends on the balance amongst cholesterol synthesis, cholesterol efflux, and cholesterol uptake from 
low-density lipoproteins9,21. Cellular cholesterol synthesis uses a series of enzymes, with the mevalonate pathway 
providing the rate-limiting process8. The mevalonate pathway initially condenses two acetyl-CoA molecules to 
form acetoacetyl-CoA, which are converted to 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) by HMG-CoA 
synthase, before HMG-CoA reductase (HMGCR, EC 1.1.1.34) yields mevalonate (Fig. 1). A series of enzymes, 
ending with farnesyl pyrophosphate synthase (FDPS, EC 2.5.1.10), then convert mevalonate to farnesyl pyrophos-
phate. Farnesyl pyrophosphate is a substrate for several enzymes, but the most important for cholesterol synthesis 
is farnesyl diphosphate farnesyltransferase 1 (FDFT1, EC 2.5.1.21), which is also called squalene synthase8,22.
We reasoned that depleting cellular cholesterol might increase the resilience of cells to PLO. The most com-
mon drugs used to reduce hypercholesterolemia regulate the mevalonate pathway include: statins, such as ator-
vastatin, which inhibit HMGCR; nitrogen-containing bisphosphonates, such as alendronate, which inhibit FDPS; 
and, zaragozic acid A, derived from fungi, which inhibit FDFT19,23–25. The present study tested the hypothesis that 
inhibiting enzymes in the mevalonate pathway to reduce cellular cholesterol increases the resilience of stromal 
cells to PLO.
Figure 1. The mevalonate pathway leads to cholesterol synthesis. Acetoacetyl CoA and acetyl CoA are 
converted to squalene, which is subsequently converted to cholesterol. Important enzymes in the pathway 
include 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), farnesyl pyrophosphate synthase 
(FDPS), and farnesyl diphosphate farnesyltransferase 1 (FDFT1, also commonly called squalene synthase). Each 
of these enzymes can be inhibited by statins, bisphosphonates, and zaragozic acid, respectively; cholesterol can 
be depleted using methyl-β-cyclodextrin (MBCD).
www.nature.com/scientificreports/
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Results
PLO causes cytolysis. To explore the resilience of stromal cells to cholesterol-dependent cytolysins, we 
chose to use primary bovine endometrial stromal cells (BESC) because they are the main target of T. pyogenes16. 
In addition, to examine whether cellular resilience mechanisms are conserved across species, we used telomer-
ase-immortalized human endometrial stromal cells (HESC)26. Using pure populations of stromal cells removes 
potential confounding effects of immune cells, and helps focus on mechanisms that impact tissue cell resilience, 
rather than immunity2,4. Recombinant pyolysin protein (PLO) was generated and purity was confirmed using 
SDS-PAGE (Supplementary Fig. S1), as described previously16,27,28. The specific activity of PLO was 628,338 HU/
mg protein, as determined using a hemolysis assay, and there was very little endotoxin contamination (1.5 EU/
mg protein).
The BESC and HESC were cultured in 24-well plates until 70% confluent and then challenged directly with 
PLO because, unlike most cholesterol-dependent cytolysins, PLO is spontaneously active without the addition 
of thiol reducing agents6,10. To limit the potential effects of cellular uptake of cholesterol or serum binding to 
PLO, serum-free media were used as described previously20,29. After challenging the cells for 2 h with a range 
of concentrations of PLO, cell viability was assessed by the mitochondria-dependent reduction of 3-(4,5-dime
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to formazan in viable cells30. In this colorimetric assay 
we defined 100% viability as the OD570 measurement for cells in control medium, and 0% viability as the OD570 for 
cells lysed using Triton X-100. We assumed that a reduction in OD570 was a reflection of cytoxicity, as described 
previously for experiments using cholesterol-dependent cytolysins16,20,31. The correlation between MTT OD570 
measurements and the number of live cells was confirmed previously using trypan blue exclusion and counting 
the number of live cells using a hemocytometer16. The percentage cell viability was calculated as the OD570 of 
PLO-treated cells relative to OD570 values for cells in control medium. The viability of BESC and HESC decreased 
in a PLO concentration-dependent manner (Fig. 2A,B). For subsequent experiments, we selected a 2 h challenge 
with 100 HU/ml PLO for BESC and 200/ml HU PLO for HESC.
We confirmed the utility of challenging BESC and HESC with 100 and 200 HU/ml PLO, respectively, by 
measuring the leakage of lactate dehydrogenase (LDH) from the cytosol into the supernatant, which is a proxy 
for the formation of pores in plasma membranes by cholesterol-dependent cytolysins32. There was increased 
abundance of LDH in the supernatants of both BESC and HESC challenged with PLO, compared with control 
(Fig. 2C,D). To verify that PLO activity is cholesterol-dependent, we also depleted cellular cholesterol by treat-
ing cells with MBCD, which binds to cholesterol and prevents the formation of pores by cholesterol-dependent 
cytolysins16,18,19,33. When BESC or HESC were treated with MBCD for 24 h, and then challenged with PLO for 2 h, 
there was no significant increase in supernatant LDH concentrations, compared with control (Fig. 2C,D).
As a control, to verify the cytolytic activity was caused by PLO, we used a mutant PLO protein, which has 
a protein-stabilizing disulphide bridge (DS-PLO), that binds to plasma membranes but does not form pores28. 
Challenging cells with PLO caused a marked reduction in viability of both cell types, whereas an equivalent 
amount of DS-PLO did not cause cytolysis (Fig. 2E,F). Taken together, these data provide evidence that BESC and 
HESC are sensitive to the cholesterol-dependent cytolysin PLO.
RNA interference of FDFT1 increases cellular resilience to PLO. We used RNA interference and 
pharmaceutical inhibitors to explore the role of the mevalonate pathway in cellular resilience to PLO. In the first 
approach, BESC and HESC were transfected with short interfering RNA (siRNA) sequences targeting key genes 
in the mevalonate pathway HMGCR, FDPS and FDFT1 (Table 1). The transfection and RNA interference tech-
nique in serum-free media did not significantly affect cell viability or cell permeability, as determined by MTT 
and LDH assays, respectively (Supplementary Fig. S2). However, mRNA expression was reduced by 48%, 90% 
and 69% with siRNA targeting HMGCR, FDPS and FDFT1, respectively, in BESC (Fig. 3A), and by 91%, 89% and 
91%, respectively, in HESC (Fig. 3B). Cellular concentrations of cholesterol were also measured to quantify the 
effectiveness of the siRNA. Each of the siRNA significantly reduced the concentrations of cholesterol in BESC and 
HESC, and the concentrations were similar to cells treated with MBCD to deplete cholesterol (Fig. 3C,D).
The BESC and HESC were next transfected with siRNA for 48 h and then challenged with PLO for 2 h. Cells 
transfected with control scramble siRNA had a reduction in cell viability when challenged with PLO, as deter-
mined by MTT assay (Fig. 3E,F), and increased accumulation of LDH in supernatants (Fig. 3G,H). Using MBCD 
to deplete cellular cholesterol as a positive control reduced the impact of PLO in BESC and HESC. As might be 
expected with primary cells, the effect of siRNA in BESC was somewhat variable. Although siRNA targeting FDPS 
did not significantly rescue BESC when challenged with PLO, depleting HMGCR and FDFT1 increased cell resil-
ience to PLO (Fig. 3E). However, depletion of HMGCR, FDPS and FDFT1 did not significantly change the BESC 
leakage of LDH when challenged with PLO (Fig. 3G). In HESC, only siRNA depletion of FDFT1 significantly 
increased cell resilience to PLO and reduced leakage of LDH (Fig. 3G,H). Together these data provide evidence 
that siRNA targeting mevalonate pathway enzymes reduces cellular cholesterol, but only depletion of specific 
enzymes, such as FDFT1, enhances stromal cell resilience to PLO.
Inhibitors of mevalonate pathway enzymes enhance cellular resilience to PLO. For our second 
approach to explore cellular resilience to PLO, we selected atorvastatin to inhibit HMGCR, the bisphosphonate 
alendronate to inhibit FDPS, and zaragozic acid to inhibit FDFT1. In order to determine if the inhibitors might 
reduce cell viability per se, BESC and HESC were incubated with the manufacturer’s recommended concentra-
tions of 1 μM atorvastatin, 10 μM alendronate and 10 μM zaragozic acid for 48 h in serum free media, prior to 
evaluating cell viability using the MTT assay. Apart from atorvastatin in HESC, the inhibitors did not significantly 
reduce BESC or HESC viability (Fig. 4A,B). However, each of the inhibitors reduced cellular cholesterol in BESC 
and HESC, compared with control (Fig. 4C,D).
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One concern with the inhibitors was that observations might be misleading if the inhibitors could bind PLO. 
To test this, each inhibitor was incubated with PLO for 1 h prior to addition of horse red blood cells and measure-
ment of hemolysis. Cholesterol was used as a positive control to bind PLO and reduce hemolysis. However, the 
mevalonate pathway inhibitors or MBCD did not significantly alter the hemolytic effect of PLO (Fig. 4E).
Having established the mevalonate pathway inhibitors could reduce cellular cholesterol, BESC and HESC 
were incubated for 48 h with a range of concentrations of atorvastatin, alendronate or zaragozic acid, prior to 
challenge with PLO for 2 h. In BESC, there was no significant effect of atorvastatin, but alendronate and particu-
larly zaragozic acid increased the resilience of cells to PLO (Fig. 5A). In HESC, there was no significant effect of 
alendronate, but atorvastatin and particularly zaragozic acid increased the resilience of cells to PLO (Fig. 5B). To 
Figure 2. The effect of PLO on stromal cells. (A) BESC isolated from 3 animals, and (B) HESC from 3 
independent passages were challenged for 2 h with control medium (■), or media containing the indicated 
concentrations of PLO ( ), and cell viability evaluated by MTT assay. Data are presented as mean (SEM), and 
analyzed by one-way ANOVA with Dunnett’s multiple comparison post-hoc test; values differ from control, 
**P < 0.01, ***P < 0.001. (C) BESC isolated from 5 animals, and (D) HESC from 3 independent passages were 
grown in control serum-free medium or medium containing methyl-β-cyclodextrin for 24 h to deplete 
cholesterol, and then challenged for 2 h with control medium (■), or media containing PLO ( ) using 100 HU/ml 
for BESC and 200 HU/ml for HESC, and leakage of LDH was measured in cell supernatants. Data are presented 
as mean (SEM), and analyzed by one-way ANOVA with Dunnett’s multiple comparison post-hoc test; values 
differ from control, **P < 0.01. (E) BESC isolated from 3 animals, and (F) HESC from 3 independent passages, 
were challenged for 24 h with control serum-free medium (■), or media containing PLO ( ) or DS-PLO (DS,  ), 
and cell viability evaluated by MTT assay. Data are presented as mean (SEM) percent viability of control, and 
analyzed by one-way ANOVA with Dunnett’s multiple comparison post-hoc test; values differ from control, 
**P < 0.01, ***P < 0.001.
www.nature.com/scientificreports/
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further examine the effect of zaragozic acid, BESC were treated for 24 h or 48 h with 10 μM zaragozic acid prior 
to challenge with PLO, and cell viability monitored hourly using the Alamar Blue assay34, which depends on the 
cellular enzymatic reduction of resazurin to resorufin (Fig. 5C,D). Cellular resilience to PLO was increased by 
24 h or 48 h treatment with zaragozic acid (ANOVA, P < 0.05, and P < 0.001, respectively).
To further explore the impact of mevalonate pathway inhibitors, BESC and HESC were incubated with control 
serum-free media, or media containing 1 μM atorvastatin, 10 μM alendronate, 10 μM zaragozic acid, or 1 mM 
methyl-β-cyclodextrin (MBCD) for 48 h, and then challenged with control medium or PLO for 2 h. The inhibitors 
per se did not significantly affect cell viability or the release of LDH in control medium (all values within 10% of 
control). However, atorvastatin and zaragozic acid reduced the impact of PLO on cell viability, as determined by 
MTT assay, in BESC (Fig. 6A) and HESC (Fig. 6B). There was also a significant reduction in the leakage of LDH 
for atorvastatin in BESC, and zaragozic acid in HESC (Fig. 6C,D). To determine whether the protection against 
PLO by mevalonate pathway inhibitors affected the number of cells, total cellular DNA was measured using the 
CyQuant assay. Total cellular DNA remained unchanged after challenge with control media or PLO (Fig. 6E,F), 
indicating that changes in viability were independent of the number of cells. Taken together, these data sup-
port a concept that the resilience of stromal cells to PLO is increased by inhibiting specific mevalonate pathway 
enzymes, particularly FDFT1.
Discussion
We found that inhibiting enzymes in the mevalonate pathway reduced cholesterol abundance in both primary 
bovine endometrial stromal cells (BESC) and telomerase-immortalized human endometrial stromal cells 
(HESC). However, surprisingly, inhibiting each mevalonate pathway enzyme did not equally affect cellular 
resilience to PLO. Inhibiting FDFT1 most consistently increased stromal cell resilience to PLO. We suggest that 
manipulating the mevalonate pathway may help tissue cells tolerate bacterial infections. We also speculate that 
topical application of FDFT1 inhibitors could be used therapeutically in the uterus.
Pyolysin is considered to be the only cytolysin secreted by T. pyogenes, as determined using an anti-PLO 
antibody or deletion of the plo gene10,16,35,36. To examine mechanisms of cellular resilience, the present study 
used stromal cells because it is important to use tissue cells that could influence the ability of tissues to tolerate 
pathogens2,4. As expected, BESC were sensitive to recombinant PLO protein16,20. However, PLO also reduced 
cellular viability and increased the leakage of LDH into supernatants of HESC. The sensitivity of HESC to PLO 
was unexpected as T. pyogenes only rarely causes disease in humans37. However, the potency of PLO across species 
and tissues may help explain the wide diversity of species and diseases that are associated with T. pyogenes infec-
tion. Although a specific cell surface receptor cannot be ruled out, the ability of exogenous cholesterol to inhibit 
hemolysis in the present study and the sensitivity of HESC to PLO, provides evidence that cholesterol is likely the 
main target of PLO.
Plasma membranes of cultured fibroblast cells from human foreskin contain half their cellular phospho-
lipid and 90% of their cholesterol and sphingomyelin7. In the plasma membrane, cholesterol is distributed 
amongst an essential pool, a sphingomyelin sequestered pool, and a labile pool of cholesterol that binds to 
cholesterol-dependent cytolysins17. We assume that this labile pool of cholesterol is most likely depleted when 
cells are treated with MBCD18. In the present study, MBCD consistently reduced cellular cholesterol abundance 
in BESC and HESC, and this was associated with increased resilience to PLO. Although MBCD has not been 
used with HESC previously, these observations are consistent with findings for BESC and other cells, and with a 
range of cholesterol-dependent cytolysins6,16,20,33. Cellular cholesterol abundance depends on cholesterol uptake 
from LDL, cholesterol efflux, and cholesterol synthesis via the mevalonate pathway8,9. Cholesterol homeostasis is 
highly regulated in cells and HMGCR is usually considered to be the rate-limiting enzyme in cholesterol synthe-
sis, although this may not apply to all cells21,22. The importance of the mevalonate pathway for cellular cholesterol 
was verified in the present study, using siRNA or inhibitors to target HMGCR, FDPS, and FDFT1 in endometrial 
stromal cells, which consistently reduced cellular cholesterol by about half; similar to the effect of MBCD.
The surprising finding in the present study was that despite siRNA and inhibitors reducing cellular choles-
terol, the effect on cellular resilience varied. Depleting FDFT1 mRNA expression or inhibiting FDFT1 activity 
Species Gene Direction Sequence (5′ → 3′)
Bos taurus HMCGR
Sense CAGCAUGGAUAUUGAACAAUU
Antisense UUGUUCAAUAUCCAUGCUG
Bos taurus FDPS
Sense GCACAGACAUCCAGGACAAUU
Antisense UUGUCCUGGAUGUCUGUGCUU
Bos taurus FDFT1
Sense GCGAGAAGGGAGAGAGUUUUU
Antisense AAACUCUCUCCCUUCUCGC
Homo sapiens HMCGR
Sense GGAUAAACCGAGAAAGAAAUU
Antisense UUUCUUUCUCGGUUUAUCC
Homo sapiens FDPS
Sense GCAGAAGGAGGCUGAGAAAUU
Antisense UUUCUCAGCCUCCUUCUGC
Homo sapiens FDFT1
Sense GCAAGGAGGAAGAGAGUUCUU
Antisense GAACUCUCUUCCUCCUUGC
Table 1. siRNA sequence for target gene knockdown.
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Figure 3. RNA interference of mevalonate pathway enzymes. (A) BESC isolated from 3 animals, and (B) HESC 
from 3 independent passages, were transfected with scramble siRNA or siRNA targeting HMGCR, FDPS or 
FDFT1. The mRNA expression of each cognate gene was measured by qPCR, and data presented as mean (SEM) 
relative to two reference genes. Data were analyzed by Student’s t-test; values differ from scramble, **P < 0.01, 
***P < 0.001. BESC isolated from 3 animals (C,E,G) or HESC from 3 independent passages (D,F,H) were 
incubated for 48 h in serum-free control medium, or media containing scramble siRNA or siRNA targeting 
HMGCR, FDPS or FDFT1, or cultured with methyl-β-cyclodextrin (MBCD) as a positive control. Cellular 
cholesterol (C,D) was measured and normalized to phospholipid concentrations, and data presented as arbitrary 
units (AU) with each dot representing an independent animal or cell passage, and a horizontal line indicating 
the mean. Cells were challenged with control media (■) or media containing PLO ( ) using 100 HU/ml for 
BESC and 200 HU/ml for HESC, for 2 h. Cell viability was quantified by MTT assay (E,F), and supernatants were 
collected to measure LDH (G,H). Data are presented as mean (SEM), and were analyzed by one-way ANOVA 
and Dunnett’s multiple comparison post-hoc test; values differ from scramble challenged with PLO,*P < 0.05, 
**P < 0.01, ***P < 0.001.
www.nature.com/scientificreports/
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Figure 4. Inhibition of mevalonate pathway enzymes. (A,C) BESC from 3 animals and (B,D) HESC from 3 
independent passages were incubated in control serum-free medium, or media containing 1 μM atorvastatin 
(AT), 10 μM alendronate (AL), 10 μM zaragozic acid (ZA) or methyl-β-cyclodextrin (MBCD) for 48 h. (A,B) 
Cell viability was assessed by MTT assay. Data are expressed as mean (SEM), and were analyzed by one-way 
ANOVA and Dunnett’s multiple comparison post hoc test; values differ from control, *P < 0.05. (C,D) Cellular 
cholesterol was measured and normalized to phospholipid concentrations, and data presented as arbitrary 
units (AU) with each dot representing an independent animal or cell passage, and a horizontal line indicating 
the mean. Data were analyzed by one-way ANOVA and Dunnett’s multiple comparison post hoc test; values 
differ from control, *P < 0.05, **P < 0.01 and ***P < 0.001. (E) The inhibitors or vehicle were incubated with 
100 HU/ml PLO for 1 h in DPBS, using 1 mM cholesterol (CHO) as a positive control and DPBS as a negative 
control (Vehicle), and then incubated with 0.5% (v/v) horse red blood cells for 1 h at 37 °C to assess hemolysis. 
Data are expressed as mean (SEM) relative hemolysis of three independent experiments.
www.nature.com/scientificreports/
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with zaragozic acid most effectively increased cellular resilience to PLO in BESC and HESC. Thus, factors other 
than the abundance of cholesterol influenced the ability of cells to tolerate PLO. One possible explanation is that 
off-target effects of the inhibitors could affect cell resilience, although this seems less likely for siRNA. Another 
possibility is that while inhibition of each enzyme reduces cholesterol synthesis, the abundance of substrates and 
products will likely vary for each enzyme. For example, inhibiting FDFT1 may lead to increased farnesyl pyroph-
osphate, whereas inhibiting HMGCR would likely reduce farnesyl pyrophosphate concentrations. In addition, 
there may be wider impacts on the pathways that regulate cholesterol homeostasis, such as sterol regulatory 
Figure 5. Mevalonate pathway inhibitors modulate the impact of PLO on cell viability. (A) BESC isolated from 
4 animals, or (B) HESC from 3 independent passages were incubated for 48 h with control serum-free medium, 
or media containing the indicated concentrations of atorvastatin, alendronate or zaragozic acid, and then 
challenged with control media (■) or media containing PLO ( ) using 100 HU/ml for BESC and 200 HU/ml for 
HESC, for 2 h. Cell viability was determined by MTT assay. Data are expressed as mean (SEM), and were 
analyzed by one-way ANOVA with Dunnett’s multiple comparison post hoc test; values differ from PLO 
treatment with no inhibitor, *P < 0.05, **P < 0.01, ***P < 0.001. In independent experiments, BESC isolated 
from 4 animals were incubated for (C) 24 h or (D) 48 h in serum-free media containing vehicle, MBCD or 
10 μM zaragozic acid. Cells were then challenged with 100 HU/ml PLO, and cell viability was monitored every 
hour using the Alamar Blue assay. Data are expressed as mean (SEM) percentage viability of control.
www.nature.com/scientificreports/
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Figure 6. Mevalonate pathway inhibitors and cellular resilience to PLO. (A,C,E) BESC from 3 animals, and 
(B,D,F) HESC from 3 independent passages were incubated with control serum-free media (0), or media 
containing 1 μM atorvastatin (AT), 10 μM alendronate (AL), 10 μM zaragozic acid (ZA) or methyl-β-
cyclodextrin (MBCD) for 48 h, and then challenged with control media (■) or media containing PLO ( ) using 
100 HU/ml for BESC and 200 HU/ml for HESC, for 2 h. Cell viability was evaluated by MTT assay (A, B), 
supernatants were collected for LDH assay (C,D), and total cell DNA was determined by CyQuant assay (E,F). 
Data are expressed as mean (SEM), and were analyzed by one-way ANOVA with Dunnett’s multiple comparison 
post hoc test; values differ from PLO treatment with no inhibitor, *P < 0.05, **P < 0.01 and ***P < 0.001; ND, 
below limits of detection.
www.nature.com/scientificreports/
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element binding proteins21. Indeed, activation of lipogenic genes by sterol regulatory element binding protein 1 
promoted cell survival after toxin attack38.
A limitation of the present study was that BESC show some variation in their susceptibility to PLO, as deter-
mined by MTT assay or LDH leakage, and the effects of modulating the mevalonate pathway. Isolation and 
culture of primary bovine endometrial stromal cells was performed as described previously39,40. Some of the 
variance may reflect differences amongst the animals from which the cells were isolated, and biological variation 
is a consistent feature of primary endometrial stromal cells function determined by MTT, LDH and cholesterol 
assays16,20,39. In addition, as BESC and HESC continue to grow during experiments, the OD570 values from the 
MTT assay also increase when there is a longer duration of the experiment. To provide additional evidence for 
our claims, future work might use more animals to isolate cells, a wider range of measurements of cell resilience, 
and use in vivo experiments.
The ability to increase tissue cell resilience so that tissues can tolerate pathogens is important for health2,4. 
Several cellular pathways increase the resilience of cells to cholesterol-dependent cytolysins, includ-
ing mitogen-activated protein kinases, the unfolded protein response, autophagy, calcium ion flux, and 
caspase-138,41–44. Unfortunately, manipulating these pathways to protect against cholesterol-dependent cytolysins 
in vivo may be challenging because inhibitors of these pathways are often toxic. However, statins are widely used 
in vivo, and simvastatin enhanced cellular resistance against the cholesterol-dependent cytolysin pneumolysin in 
human endothelial cells45. Similarly, simvastatin or siRNA targeting HMGCR protected human airway epithelial 
cells against pneumolysin29. Interestingly, and in accord with our findings, the protective mechanism of simvas-
tatin was not solely mediated by reducing cellular cholesterol29. Furthermore, Statt et al. (2015) also found that 
an inhibitor of FDFT1 or siRNA depleting FDFT1 mRNA reduced the impact of pneumolysin on cells29. In the 
present study, zaragozic acid increased the resilience of both BESC and HESC to PLO, and was not toxic to cells 
at the concentrations we used.
Interestingly, zaragozic acid also reduces BESC inflammatory responses to endotoxin from Gram-negative 
bacteria46; and, reduces serum cholesterol concentrations in vivo25. Thus, zaragozic acid might be worthy of fur-
ther investigation to increase tissue tolerance to bacteria. One therapeutic advantage with uterine infections is 
that treatments are often topical applications, via intrauterine infusion, which provides high concentration of the 
pharmaceutical molecule with less risk of toxicity11. We suggest that intrauterine infusion of inhibitors targeting 
mevalonate pathway enzymes could be used to limit the severity of uterine disease caused by T. pyogenes in post-
partum animals. An alternative approach would be to infuse MBCD or other cyclodextrins that deplete choles-
terol. However, cyclodextrins can also act as cholesterol donors, with the danger of toxicity19.
In conclusion, the present study provides evidence that manipulating the mevalonate pathway increases the 
resilience of cells to PLO, to help tissues tolerate bacterial infections. We speculate that inhibitors of the meva-
lonate pathway could be used to increase cellular resilience to cholesterol-dependent cytolysins, and limit the 
severity of disease.
Methods
Pyolysin. The PLO plasmid (pGS59) was a generous gift from Prof BH Jost (University of Arizona, USA), 
and the DS-PLO mutant plasmid (R219C/G85C) was a kind gift from Prof M Palmer (University of Waterloo, 
Canada). Proteins were generated as described previously16,27,28. The abundance of proteins was measured by DC 
assay, and their purity evaluated using SDS-PAGE and Coomassie blue staining, as described previously16.
A hemolysis assay was used to determine the activity of PLO, as described previously16. Optical density (OD450) 
was measured using a microplate reader (POLARstar Omega; BMG Labtech, Offenburg, Germany). Hemolytic 
units were mathematically determined by 4-parameter modelling using the Solver function in Microsoft Excel. 
Endotoxin concentrations in stock solutions of PLO were all <1 EU/ml, as determined by LAL assay (LAL endo-
toxin quantitation kit; Thermo Scientific, Hertfordshire, UK). To examine the potential binding to PLO, 1 μM 
atorvastatin, 10 μM alendronate, 10 μM zaragozic acid, 1 mM methyl-β-cyclodextrin, and 1 mM cholesterol (all 
Sigma) were incubated with 100 HU/ml PLO for 1 h, prior to conducting the hemolysis assay.
Ethical statement. No live animal experiments were conducted. Uteri were collected from cattle after they 
were slaughtered and processed as part of the normal work of an abattoir.
Cell culture. Isolation and culture of primary bovine endometrial stromal cells was performed as described 
previously39,40. Briefly, uteri with no gross evidence of genital disease or microbial infections were collected from 
cattle after they were slaughtered and processed as part of the normal work of an abattoir. No live animal experi-
ments were used. Stromal cells were isolated by enzymatic digestion of the endometrium, sieving the cell suspen-
sion through a 40-μm mesh, and differential adhesion to cell culture plates39,40. Stromal cells were maintained in 
BESC complete culture medium comprising RPMI-1640 (Gibco, Gaithersburg, MD, USA) with 10% fetal bovine 
serum, and 50 IU/ml penicillin, 50 µg/ml streptomycin and 2.5 µg/ml amphotericin B (all Sigma). Cells were 
incubated at 37°C in humidified air with 5% CO2.
The HESC cells were generously gifted by Dr G Krikun (Yale University School of Medicine, USA; ATCC 
cell line CRL-4003) and were cultured as described previously26. Briefly, cells were grown in 75 cm2 tis-
sue culture flasks containing HESC complete culture medium, comprising a 1:1 mixture of Dulbecco’s mod-
ified Eagle’s medium and Ham’s F-12 medium (Gibco), supplemented with 12% fetal bovine serum, 1% 
insulin-transferrin-selenium-ethanolamine (ITS-X; Gibco), 50 IU/ml penicillin, 50 µg/ml streptomycin, and 
2.5 µg/ml amphotericin B. Cells were incubated at 37°C in humidified air with 5% CO2, and used for up to 30 
passages. The identity of HESC was verified at the end of the project by short tandem repeat profiling (LGC 
Standards, Teddington, UK; FTA barcode STRA1969; exact match to ATCC human cell line CRL-4003).
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Cell experiments. To examine cellular resilience, BESC and HESC were seeded at a density of 50,000 cells 
per well in 24-well tissue culture plates (TPP, Trasadingen, Switzerland), and were cultured for 24 h in their 
respective complete culture media. Cells were then incubated in serum free media with atorvastatin, alendro-
nate or zaragozic acid, using the concentrations and durations indicated in Results, prior to challenge with con-
trol medium or medium containing PLO. Methyl-β-cyclodextrin was used to deplete cellular cholesterol, using 
0.5 mM for BESC and 1 mM for HESC. Alternatively, BESC and HESC were transfected with scramble siRNA 
(ON-TARGETplus Non-targeting siRNA #1; Dharmacon; gelifesciences.com) or siRNA targeting HMCGR, FDPS 
or FDFT1, which were designed using Dharmacon’s siDESIGN Center (Table 1). Briefly, duplex complexes were 
formed by adding 100 pM of siRNA to 500 μl/well Opti-MEM I medium (Invitrogen, Waltham, MA) in 6-well 
plates (TPP), and then adding 7.5 μl Lipofectamine RNAiMAX Reagent (Invitrogen). Following 20 min incuba-
tion at room temperature, 250,000 exponentially growing cells were then seeded in 2.5 ml/well of their respective 
complete media for 48 h, prior to challenge with control medium or medium containing PLO.
Cell viability assays. Cell viability was assessed by the mitochondria-dependent reduction of 3-(4,5-dime
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) to formazan, as described previously30. Briefly, 
once supernatants were collected, the remaining cells were incubated for 2 h in 250 μl/well serum-free culture 
medium containing 1 mg/ml MTT; the medium was then removed and the cells lysed with 250 μl/well dimethyl 
sulfoxide (Sigma); and, optical density (OD570) measured using a POLARstar Omega microplate reader.
The kinetics of cell survival was examined by enzymatic reduction of resazurin to resorufin using the Alamar 
Blue cell viability assay (Pierce, Rockford, IL, USA)34. Fluorescence was measured at 545/590 nm (excitation/
emission) using a POLARstar Omega microplate reader, with data expressed as the percentage of control cell 
survival.
Total cellular DNA concentrations were measured using the CyQuant Cell Proliferation Assay (Thermo Fisher 
Scientific, Loughborough, UK). Fluorescence was measured at 480/530 nm (excitation/emission), with data 
expressed as arbitrary fluorescence units.
Leakage of cellular LDH was measured in cell culture supernatants using the Lactate Dehydrogenase Activity 
Colorimetric Assay Kit (Biovision, California, USA), according to the manufacturer’s instructions.
Cholesterol measurement. The BESC and HESC were grown at a density of 100,000 cells/well in 12-well 
tissue culture plates and treated with siRNA or inhibitors, as described above. After the treatment period, the cells 
were collected in 200 µl/well 1X cholesterol assay buffer and stored in Eppendorf tubes at −20°C. When needed, 
the samples were defrosted at room temperature and sonicated for 10 min in a sonicating water bath. Cellular 
cholesterol content was measured using the Amplex® Red Cholesterol Assay Kit (Invivogen), according to the 
manufacturer’s guidelines. Total cellular phospholipid was measured in the samples prepared for the cholesterol 
assay using a phospholipid assay kit (Sigma Aldrich, MAK122), according to the manufacturer’s guidelines. The 
cholesterol concentrations were then normalized to the phospholipid concentrations, and the data are expressed 
as arbitrary units.
Quantitative PCR (qPCR). Cellular RNA was extracted using the RNeasy Mini Kit according to the manu-
facturer’s instructions (Qiagen, Crawley, UK). The RNA was quantified using a Nanodrop ND1000 spectropho-
tometer (Labtech, Ringmer, UK), and 1 μg of total RNA added to a genomic DNA elimination reaction, followed 
Species Gene Direction Sequence (5′ → 3′)
Bos taurus ACTB
Forward CAGAAGGACTCGTACGTGGG
Reverse TTGGCCTTGGGGTTCAGGG
Bos taurus RLP19
Forward TGTTTTTCCGGCATCGAGCCCG
Reverse ATGCCAACTCCCGCCAGCAGAT
Bos taurus HMCGR
Forward TGAGATCCGGAGGATCCGAG
Reverse CAGATGGTCAGCGTCACTGT
Bos taurus FDPS
Forward ATGACGGGTAAGATCGGCAC
Reverse TTCTGCCCATAGTTCTCCTGC
Bos taurus FDFT1
Forward GGCACCCTGAGGAGTTCTAC
Reverse GCATACTGCATGGCGCATTT
Homo sapiens ACTB
Forward ATGATGATATCGCCGCGCTC
Reverse CCACCATCACGCCCTGG
Homo sapiens RLP19
Forward GCGAGCTCTTTCCTTTCGCT
Reverse TGCTGACGGGAGTTGGCATT
Homo sapiens HMCGR
Forward GTTAACTGGAGCCAGGCTGA
Reverse CCTTGGATCCTCCAGATCTCAC
Homo sapiens FDPS
Forward GAGACCGGGCCTTACTTCTG
Reverse GGACAGGGGCATCCTTCAAA
Homo sapiens FDFT1
Forward GACTCGACAGACTCTAAGGCTC
Reverse TGGTCAATAAGTCGCCCACG
Table 2. Sequence of target and house-keeping primers.
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by conversion to cDNA (Quantitect Reverse Transcription Kit, Qiagen), according to the manufacturer’s instruc-
tions. Quantitative PCR was performed using intron-spanning primers (Table 2) and the IQ5 system (Bio-Rad, 
Hemel Hempstead, UK). The starting quantity of mRNA was determined using standard curves generated from 
serial dilutions of pooled reference RNA with Quantifast SYBR green (Qiagen). The target and reference genes 
were analyzed in triplicate, and mRNA expression normalized to the ACTB and RPL19 reference genes (Table 2) 
using the IQ5 system (Bio-Rad), with inter-run correlation and run-dependent differences corrected using qBase 
software on the IQ5 system (Bio-Rad)47. The reference genes did not differ in expression with treatment, and were 
amplified at the same efficiency as the target genes.
Statistical analysis. Data are presented as arithmetic mean and error bars represent SEM. The statistical 
unit was designated as the animal for BESC, and each independent cell passage for HESC. Statistical analysis 
was performed using Graphpad Prism 5.0.1 and SPSS 20.0, with P < 0.05 considered statistically significant. 
Comparisons between two treatments were tested using Student’s t-test, and amongst several treatments using 
ANOVA, followed by Dunnett’s post hoc multiple comparison test.
Data availability. All data generated or analyzed during this study are included in this published article (and 
its Supplementary Information files).
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Supplementary Figure S1. The purity of PLO protein. The purity of recombinant PLO 
protein produced in Escherichia coli was evaluated using SDS-PAGE and Coomassie blue 
staining. Soluble fractions were diluted to 20 μg/μl in a 1:1 ratio with Laemelli sample buffer 
and heated to 95˚C for 10 min before loading onto 12% Mini-PROTEAN® TGX™ precast 
gel. A Dual colour standard ladder was used as marker, and a sample volume of 20 µl was 
loaded in each well and run at 120V until the dye front reached the bottom of the gel. SDS-
PAGE gels were stained overnight in Coomassie stain (50% (v/v) dH2O, 40 (v/v) methanol, 
10% (v/v) acetic acid and 0.5% (w/v) Coomassie blue R250), and destained with destain 
solution (50% (v/v) dH2O, 40 (v/v) methanol and 10% (v/v) acetic acid) until clear. The 
second fraction was used in the present studies. 
 
 
 
  
Supplementary Figure S2. RNA interference of BESC and HESC.  The effect of 
siRNA transfection on cell viability was determined by incubating BESC from 4 animals 
(A, C) or HESC from 4 independent passages (B, D) for 48 h in control medium, medium 
containing lipofectamine, or transfecting cells with scramble siRNA or siRNA targeted 
against HMGCR, FDPS or FDFT1. Cells were challenged with control media (black bars) 
or media containing PLO (red bars) using 100 HU for BESC and 200 HU for HESC, for 2 
h. Cell viability was determined by MTT assay (A, B), and cell permeability by measuring 
LDH in cell supernatants (C, D). Data are expressed as mean (SEM).  
 
